4:41 PM
 | 
Aug 21, 2013
 |  BC Extra  |  Top Story

Incyte leaps on ruxolitinib pancreatic cancer data

Incyte Corp. (NASDAQ:INCY) jumped $9.05 (34%) to $36.05 on Wednesday after reporting that ruxolitinib plus capecitabine significantly improved the primary endpoint of overall survival (OS) vs. capecitabine plus placebo in a pre-specified subgroup of patients in the Phase II RECAP trial to treat...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >